Tatalaksana Kraniektomi Dekompresif pada Pasien Cedera Otak Traumatik Berat yang Disertai Peningkatan Tekanan Tinggi Intrakranial Menetap
Abstract
Tekanan tinggi intrakranial menetap adalah penyebab kematian terbesar pada pasien dengan cedera kepala traumatik berat. Pada cedera kepala berat, tatalaksana secara konservatif dan operatif dilakukan untuk meminimalisir terjadinya cedera otak sekunder. Peningkatan tekanan intrakranial biasanya disebabkan karena edema otak, hal ini sangat penting dan menentukan hasil luaran pasien/Glasgow outcomes scale (GOS) atau Extended GOS (GOSE). Data klinis menunjukkan bahwa kraniektomi dekompresif menurunkan angka kematian, meningkatkan fungsi pemulihan, menurunkan durasi perawatan di ICU dan meningkatkan hasil luaran berdasarkan Barthel Index Score. Kraniektomi dekompresif sering dilakukan sebagai penyelamatan empiris untuk melindungi kerusakan otak lebih lanjut akibat efek edema dan hipertensi intrakranial menetap. Konsep utama tatalaksana pasien dengan tekanan tinggi intrakanial yang menetap adalah menjaga aliran darah otak dan tekanan perfusi otak.
Decompressive Craniectomy Management in Patients with Severe Traumatic Brain Injuries Accompanied by Refractory Intracranial Hypertension
Refractory intracranial hypertension is the biggest cause of death in patients with severe traumatic head injury. In severe head injuries, conservative management and surgery are performed to minimize the occurrence of secondary brain injury. The increase in intracranial pressure is usually caused by brain edema, this is very important and determines the outcomes of the Glasgow outcomes scale (GOS) or extended GOS (GOSE). Clinical data show that decompressive craniectomy reduces mortality, improves recovery function, decreases duration of ICU treatment and increases outcome outcomes based on the Barthel Index Score. Decompressive craniectomy is often performed as an empirical salvage to protect further brain damage due to the effects of edema and refractory intracranial hypertension. The main concept of managing patients with refractory intracranial hypertension is to maintain cerebral blood flow and cerebral perfusion pressure.
Keywords
Full Text:
PDFReferences
Fleseriu M, Gadelha M. Acromegaly, a pituitary special issue. Pituitary 2017; 20: 2–3.
Găloiu S, Poiană C. Current therapies and mortality in acromegaly. J. Med. Life 2015; 8: 411–5.
Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. International Journal of Endoclinology 2012; 2012.
Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology 2015; 101: 87–104.
Raffa Rb, Rawis SM, Beyazarof EP. Netter’s Illustrated Pharmacology, 2014; 57–91.
Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary 2017; 20:4–9.
Sav A, Rotondo F, Syro LV, Di Ieva A, Cusimano MD, Kovacs K. et al. Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol. Metab. Clin. North Am 2015; 44: 99–104.
Pastuszak AW, Liu JS, Vij A, Mohamed O, Sathyamoorthy K, Lipshultz LI. et al. IGF-1 levels are significantly correlated with patient-reported measures of sexual function. Int. J. Impot. Res 2011; 23: 220–26.
Terzolo M, Reimondo G, Berchialla P, Ferrante E, Malchiodi E, De Marinis L. et al. Acromegaly is associated with increased cancer risk: A survey in Italy. Endocr. Relat. Cancer 2017; 24: 495–504.
Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CM, Pinedo AC. et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 2016; 19: 448–57.
Hannon AM, Thompson CJ & Sherlock M. Diabetes in Patients With Acromegaly. Curr. Diab. Rep 2017; 17: 8.
Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A. et al. A consensus on the medical treatment of acromegaly. Nat. Publ. Gr 2014; 10: 243–48.
Danzig BJ. New guidelines for the treatment of acromegaly, a serious growth hormone disorder 2011; 1–7.
Tang JA. & Friedman M. Incidence of Lingual Tonsil Hypertrophy in Adults with and without Obstructive Sleep Apnea. Otolaryngol. Neck Surg 2018; 158: 391–94.
Ghatak T, Samanta S, Samanta S. & Bhagat H. Extubation difficulty after transphenoidal pituitary surgery in an acromegalic patient. Indian J. Anaesth 2013; 57: 322–23.
Molitch ME. Diagnosis and treatment of pituitary adenomas: A review. JAMA - J. Am. Med. Assoc 2017; 317: 516–24.
Giustina A, Arnaldi G, Bogazzi F, Cannavo S, Colao A, De Marinis L. et al. Pegvisomant in acromegaly: an update. J. Endocrinol. Invest. 2017; 40: 577–89.
Katznelson L, Laws ER jr, Melmed S, Molitch ME, Murah MH, Utz A. et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab 2014; 99: 3933–51.
Sherlock M, Reulen RC, Aragon-Alonso A, Ayuk J, Clayton RN, Sheppard MC. et al. A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J. Clin. Endocrinol. Metab 2014; 99: 478–85.
Friedel ME, Johnston DR, Singhal S, Al Khalili K, Farrell CJ, Evans JJ, et al. Airway management and perioperative concerns in acromegaly patients undergoing endoscopic transsphenoidal surgery for pituitary tumors. Otolaryngol. Neck Surg 2013; 149: 840–44.
DOI: https://doi.org/10.24244/jni.vol7i3.19
Refbacks
- There are currently no refbacks.
JNI is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License